



**CANSEARCH**

fondation de recherche  
contre le cancer de l'enfant

## CANSEARCH RESEARCH GRANT 2026

### PROJECT DESCRIPTION

<b>PROJECT TITLE</b> Use Times New Roman, 12 point font throughout this form.	
<b>PROJECT TYPE</b> Please tick all appropriate options for your study	
Pre-clinical Study: <input type="checkbox"/> Yes <input type="checkbox"/> No It includes, <input type="checkbox"/> In-vitro <input type="checkbox"/> In -vivo Cantonal Veterinary office approval: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, specify the Form B No: _____	Clinical study: <input type="checkbox"/> Yes <input type="checkbox"/> No It includes, <input type="checkbox"/> Clinical data <input type="checkbox"/> Biological sample Is it interventional: <input type="checkbox"/> Yes <input type="checkbox"/> No Ethical Committee approval: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify the CER number: _____
<b>PROJECT DETAILS</b>	
New project or continuation:	
Project start date:	
Duration in months:	

<b>PRINCIPAL INVESTIGATOR</b>	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

<b>CO-RESEARCHER</b>	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	
<b>CO-RESEARCHER</b>	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	
<b>CO-RESEARCHER</b>	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	
<b>CO-RESEARCHER</b>	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

**EXCLUDED REVIEWERS**  
 If you wish to exclude certain reviewers from the evaluation process, please provide their exact names, work affiliations, email addresses and brief reason for exclusion below.

**EXCLUDED REVIEWER 1:**

Name:	Email Address:
Department:	Institution:
Reason:	

**EXCLUDED REVIEWER 2:**

Name:	Email Address:
Department:	Institution:
Reason:	

**EXCLUDED REVIEWER 3:**

Name:	Email Address:
Department:	Institution:
Reason:	

**FUNDING AMOUNT REQUESTED**

Cost item	Year 1 (2026)	Year 2 (2027)	Total cost (CHF)
<b>Expenses total (CHF)</b>			

**FUNDING AMOUNT REQUESTED AND ALREADY OBTAINED**

Name of the organisation:	Amount:
---------------------------	---------

**FUNDING AMOUNT REQUESTED BUT NOT (YET) OBTAINED**

Name of the organisation:	Amount:
---------------------------	---------

**1. SUMMARY OF THE PROJECT (= ABSTRACT)**

Use Times New Roman, 12 point font, single spaced

**Maximum 1 page**

**2. BRIEFLY DESCRIBE THE BACKGROUND AND THE CURRENT STATUS OF KNOWLEDGE (RESULTS ALREADY ACHIEVED) OF THE PROJECT**

Use Times New Roman, 12 point font, single spaced  
**Maximum 2 pages**

- a. Background of research of the project
- b. Current status of knowledge (results already achieved/known) of the project



### **3. HYPOTHESIS OF THE PROJECT**

Use Times New Roman, 12 point font, single spaced

**Maximum 100 words**

#### **4. OUTLINE THE PROJECT'S OBJECTIVES**

Use Times New Roman, 12 point font, single spaced  
**Maximum 1 page**

**5. OUTLINE THE METHODOLOGY TO BE USED TO CARRY OUT THE PROJECT**

including if applicable:

biomarker study design, study population, sample size and power calculation, treatment plan/evaluation, tissue collection/handling/analysis, imaging collection/review/analysis, statistical analysis plans, number of patients involved in the study and identification of the beneficiaries

Use Times New Roman, 12 point font, single spaced

**Maximum 2 pages**



## 6. OUTLINE THE MILESTONES, KEY PERFORMANCE INDICATORS AND RISKS OF THE PROJECT


Please use a figure to show the milestones with actions and schedule

Use Times New Roman, 12 point font, single spaced

Maximum 2 pages

a. Milestones (with a figure, as the following example)

### Tasks:



### Schedule and milestones:

10/2017	04/2018	04/2019	04/2020	04/2021	03/2022
<b>Before start:</b> <b>1</b> Establish structures with all involved collaborators for data exchange and analysis <b>2</b> Ethical approval GECCOS project <b>3</b> Training of clinical centers	<b>First year:</b> <b>4</b> Finalization of all agreements between stakeholders of the Swiss childhood cancer data network (by 06/2018) <b>5</b> Data and DNA sample collection established, recruitment open at all participating centers (by 06/2018) <b>6</b> Establishment of appropriate cell lines for <i>in vitro</i> assays (by 06/2018) <b>7</b> Fully functional data exchange (by 12/2018) <b>8</b> Sensitivity testing of cell lines to lung toxic treatment and resistant cell line creation (by 12/2018)	<b>Second year:</b> <b>9</b> Publication writing of workflow establishment and its evaluation (by 06/2019) <b>10</b> <i>In vitro</i> gene expression analysis (by 06/2019) <b>11</b> Full clinical dataset and all DNA samples collected (n=896; by 12/2019) <b>12</b> Germline DNA whole-genome sequencing completed (by 03/2020) <b>13</b> <i>In vitro</i> sensitivity to lung toxic treatment after knockout/ silencing of candidate genes (by 04/2020)	<b>Third year:</b> <b>14</b> Genotyping and variant calling (by 09/2020) <b>15</b> Clinical dataset cleaning and genotype-phenotype association analysis (by 12/2020) <b>16</b> Replication analyses in SJLIFE cohort (by 03/2021) <b>17</b> Cell apoptosis testing assays on cells after knockout/ silencing of candidate genes (by 04/2021)	<b>Fourth year:</b> <b>18</b> DNA sampling established for new patients (n=250/y; by 06/2021) <b>19</b> Publication writing GECCOS project (by 06/2021) <b>20</b> Publication writing functional studies (by 12/2021) <b>21</b> DNA collection completed in remaining cohort of Swiss CCS (n=6'916, by 03/2022)	

- b. Key performance indicators (e.g. number of samples collected and number of samples analysed, collaborations to come, follow-up of the publications, funding obtained, etc.)
- c. Risks (not to achieve the project's objectives, but risks for the patient/family) and measures to be taken to tackle them



**7. BRIEFLY DESCRIBE THE EXPECTED RESULTS AND IMPACTS / SIGNIFICANCE**

Use Times New Roman, 12 point font, single spaced

**Maximum 1 page**

**8. REFERENCES LIST**

Use Times New Roman, 12 point font, single spaced